Clinical Trials
2 trialsNCT07170293 2025-09-12
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT00096941 2015-06-11
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
Genentech, Inc.
Phase 2 Completed